|
|
| | Naftopidil-d5 Basic information |
| Product Name: | Naftopidil-d5 | | Synonyms: | 1,1,2,3,3-pentadeuterio-1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-naphthalen-1-yloxypropan-2-ol | | CAS: | 2747918-58-5 | | MF: | C24H23D5N2O3 | | MW: | 397.52 | | EINECS: | | | Product Categories: | | | Mol File: | 2747918-58-5.mol |  |
| | Naftopidil-d5 Chemical Properties |
| Boiling point | 602.772±55.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.185±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | solubility | Methanol: soluble |
| | Naftopidil-d5 Usage And Synthesis |
| Uses | Naftopidil-d5 is deuterium labeled Naftopidil. Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia[1][2]. | | References | [1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110
[2] R Takei, et al. Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors. Jpn J Pharmacol. 1999 Apr;79(4):447-54. DOI:10.1254/jjp.79.447
[3] Yasuhide Hori, et al. Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma. Cancer Prev Res (Phila). 2011 Jan;4(1):87-96. DOI:10.1158/1940-6207.CAPR-10-0189
[4] MASUMORI N. Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia.[J]. Therapeutics and Clinical Risk Management, 2011, 7: 227-238. DOI: 10.2147/tcrm.s13883
[5] IKUNOBU MURAMATSU Shigcru K Kyozo Yamanaka. Pharmacological Profile of the Novel α-Adrenoceptor Antagonist KT-611 (Naftopidil)[J]. Japanese journal of pharmacology, 1991, 55 3: Pages 391-398. DOI: 10.1016/s0021-5198(19)39941-x
[6] HIDEKI KANDA. Naftopidil, a selective α-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest[J]. International Journal of Cancer, 2007, 122 2: 444-451. DOI: 10.1002/ijc.23095 |
| | Naftopidil-d5 Preparation Products And Raw materials |
|